

AD_____

Award Number: DAMD17-03-1-0256

TITLE: Treatment of Primary and Metastatic Breast Cancer by an
Armed Replicating Adenoviral Vector

PRINCIPAL INVESTIGATOR: Joanne T. Douglas, Ph.D.

CONTRACTING ORGANIZATION: University of Alabama at Birmingham
Birmingham, Alabama 35294-0111

REPORT DATE: October 2004

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 2004	3. REPORT TYPE AND DATES COVERED Final (1 Apr 2003 - 30 Sep 2004)	
4. TITLE AND SUBTITLE Treatment of Primary and Metastatic Breast Cancer by an Armed Replicating Adenoviral Vector			5. FUNDING NUMBERS DAMD17-03-1-0256	
6. AUTHOR(S) Joanne T. Douglas, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Alabama at Birmingham Birmingham, Alabama 35294-0111 E-Mail: Joanne.douglas@ccc.uab.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Original contains color plates: All DTIC reproductions will be in black and white.				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Oncolytic replication-selective adenoviruses are a new class of anticancer agents with great therapeutic potential. The ability of replication-selective viruses to amplify the initial viral dose has been exploited by engineering oncolytic adenoviruses to deliver therapeutic transgenes. In this Exploration Award, we are testing the concept that an oncolytic adenovirus can be armed with a therapeutic gene that will exert a systemic effect in the treatment of breast cancer. Breast cancer most commonly metastasizes to the skeleton. Thus, a treatment that combines eradication of the primary tumor with inhibition of osteolytic bone metastases would be a highly beneficial addition to the therapeutic armamentarium. We hypothesize that an oncolytic adenovirus armed with the osteoprotegerin (OPG) gene would be able to eradicate a primary breast cancer tumor by oncolysis, and that secretion of OPG from the infected and lysed cells into the systemic circulation would inhibit osteolytic bone metastases of the breast cancer. Thus, we propose a new class of therapeutic agent for the treatment of breast cancer. To date, we have constructed a replication-defective adenoviral vector expressing human OPG fused with the Fc domain of human IgG, and have evaluated the efficacy of the armed replicating adenoviral vector <i>in vitro</i> .				
14. SUBJECT TERMS Oncolysis, replication-selective adenovirus, adenoviral vector, bone metastasis				15. NUMBER OF PAGES 13
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

TABLE OF CONTENTS

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	9
Reportable Outcomes.....	10
Conclusions.....	11
References.....	12
Appendices.....	13

INTRODUCTION

Oncolytic replication-selective adenoviruses are a new class of anticancer agents with great therapeutic potential. The selective replication of the viruses in cancer cells amplifies the initial viral inoculum, leading to destruction of the infected cells by virus-mediated lysis. The viral progeny are thereby released and can spread through the tumor mass to infect neighboring cancer cells, resulting in self-perpetuating cycles of infection, replication and oncolysis. The ability of replication-selective viruses to amplify the initial viral dose has been exploited by engineering oncolytic adenoviruses to deliver therapeutic transgenes. To date, such "armed" oncolytic adenoviruses have been designed to carry therapeutic genes that will augment the virus-mediated eradication of the primary tumor mass. Replication-competent adenoviruses have been shown to yield levels of transgene expression up to three orders of magnitude greater than corresponding replication-defective vectors. In this Exploration Award, we propose to test the concept that an oncolytic adenovirus can be armed with a therapeutic gene that will exert a systemic effect in the treatment of breast cancer. Breast cancer most commonly metastasizes to the skeleton. Thus, a treatment that combines eradication of the primary tumor with inhibition of osteolytic bone metastases would be a highly beneficial addition to the therapeutic armamentarium. We have previously shown that osteoprotegerin (OPG) can inhibit osteolytic bone metastases in a murine model. We hypothesize that an oncolytic adenovirus armed with the OPG gene would be able to eradicate a primary breast cancer tumor by oncolysis, and that secretion of OPG from the infected and lysed cells into the systemic circulation would inhibit osteolytic bone metastases of the breast cancer. Thus, we propose a new class of therapeutic agent for the treatment of breast cancer.

BODY

Task 1. Derivation of an adenoviral vector expressing OPG-Fc

- a. Construction of vector.**
- b. Validation of vector.**
- c. Propagation of vector.**

A gene encoding the leader peptide and extracellular domains of human osteoprotegerin fused to the Fc domain of human IgG1 [1] was generated by overlap extension PCR using plasmid DNA templates that we already possess. A replication-defective adenoviral vector expressing OPG-Fc under the control of the constitutive CMV promoter was then constructed with the AdEasy system [2], which we use routinely in our laboratory. The recombinant Ad-OPG vector was validated by DNA sequencing. Expression and secretion of OPG-Fc was confirmed by infection of 911 cells. The presence of OPG-Fc in the infected cells and in the culture medium was detected by immunoblot analysis using an anti-OPG antibody (Fig. 1).





Fig. 1. Expression of OPG-Fc by adenoviral vector. 911 cells were mock-infected (lane 1) or infected with Ad-OPG at a multiplicity of infection of 100 (lane 2) or 1000 (lane 3) particles per cell. Forty-eight hours post-infection, conditioned media and cell lysates were subjected to immunoblot analysis using an anti-OPG antibody.

The ability of the OPG-Fc secreted by infected cells to bind its cognate ligand, receptor activator of nuclear factor kappaB ligand (RANKL) was confirmed in a pull-down assay (Fig. 2).

Primary Ab: Anti-OPG

- 1. Uninfected
- 2. Ad-OPG-Fc



Primary Ab: Anti-sRANKL

- R sRANKL
- 1. Uninfected
- 2. Ad-OPG-Fc




Fig. 2. OPG-Fc binds RANKL. Medium from cells infected with Ad-OPG was incubated with soluble RANKL. Fc-containing complexes were pulled down with protein G-agarose beads and then subjected to immunoblot analysis with antibodies against OPG or sRANKL.

- Task 2. Evaluation of the efficacy of the armed replicating adenoviral vector *in vitro***
- Perform *in vitro* experiments to determine oncolytic potency.**
 - Perform *in vitro* experiments to determine expression of OPG.**

Monolayers of MDA-MB-231 breast cancer cells were infected with a wild-type adenovirus (Ad300wt) plus the AdOPG vector, with the wild-type adenovirus alone, or with the AdOPG vector alone. We wished to confirm that expression of OPG does not inhibit the oncolytic potency of the replicating adenovirus. Hence, we measured the level of adenoviral DNA (Fig. 3), and performed both qualitative (Fig. 4) and quantitative (Fig. 5) assays of the numbers of viable cells eight days post-infection of the cells at a low multiplicity of infection (MOI). These assays confirmed that expression of OPG does not inhibit the oncolytic potency of the replicating adenovirus.




Fig. 3. Expression of OPG does not affect adenoviral DNA replication. Monolayers of MDA-MB-231 cells were coinfectd with Ad300wt and AdOPG at the MOIs shown. Eight days later, DNA was extracted and subjected to quantitative real-time PCR to determine the copy number of the viral E1A gene, normalized for cellular actin.




Fig. 4. Expression of OPG does not affect the oncolytic potency of a replicating adenovirus. Monolayers of MDA-MB-231 cells were coinfectd with Ad300wt and AdOPG at the MOIs shown. Eight days later, viable cells were stained with crystal violet.




Fig. 5. Expression of OPG does not affect the oncolytic potency of a replicating adenovirus. Monolayers of MDA-MB-231 cells were coinfectd with Ad300wt and AdOPG at the MOIs shown. Eight days later, viable cells were quantified in an MS assay.

Having completed the first two specific aims of the proposal, we are now initiating the third specific aim, to evaluate the efficacy of the armed replicating adenoviral vector *in vivo*.

KEY RESEARCH ACCOMPLISHMENTS

- Construction of a replication-defective adenoviral vector expressing human OPG fused with the Fc domain of human IgG.
- Demonstration that expression of OPG does significantly affect the oncolytic potency of the replicating adenovirus.
- Demonstration that OPG is expressed at a higher level by the replicating virus than by the replication-defective virus.

REPORTABLE OUTCOMES

- Published abstract and poster presentation at the annual meeting of the American Society of Gene Therapy, Minneapolis, MN, June 2-6, 2004: Cody JJ, Lyons GR and Douglas JT (2004). A dual-action armed replicating adenovirus for the treatment of bone metastases of breast cancer. Molecular Therapy 9(S1): S370, #968.
- The data generated in the work supported by this award form the basis of an application for an R01 from the NIH.

CONCLUSIONS

We have performed preliminary experiments to explore the concept that a replication-selective adenovirus armed with the OPG gene could both eradicate primary breast cancer tumors by oncolysis and inhibit osteolytic bone metastases of breast cancer. While the final form of this novel therapeutic agent will be a single virus, a breast cancer-selective replicating adenovirus carrying the OPG gene, we have employed a two-component model system in these proof-of-concept studies. In this regard, coinfection of cells with a wild-type adenovirus and a replication-defective E1-deleted adenoviral vector expressing OPG allows replication of the vector as a result of trans-complementation by the viral E1 proteins expressed by the wild-type virus.

We first constructed a replication-defective adenoviral vector expressing human OPG fused with the Fc domain of human IgG to prolong its half-life in the bloodstream. It is important that the expression of OPG should not impair the oncolytic potency of the replicating adenovirus in breast cancer cells. In addition, we wish to confirm that a greater level of OPG will be expressed by a replicating virus than by a replication-defective adenoviral vector. Hence, we perform *in vitro* studies to confirmed these two key indicators of the efficacy of the novel therapeutic agent. We will now determine whether the armed replicating adenoviral vector can treat primary and metastatic breast cancer in a murine model.

REFERENCES

1. Emery JG, McDonnell P, Brigham Burke M, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC and Young PR (1998). Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. *J Biol Chem* 273: 14363-14367.
2. He T-C, Zhou S, da Costa LT, Yu J, Kinzler KW and Vogelstein B (1998). A simplified system for generating recombinant adenoviruses. *Proc Natl Acad Sci USA* 95: 2509-2514.

[968] A Dual-Action Armed Replicating Adenovirus for the Treatment of Bone Metastases of Breast Cancer

James J. Cody, Gray R. Lyons, Joanne T. Douglas Department of Pathology, University of Alabama at Birmingham, Birmingham, AL; Davidson College, Davidson, NC; Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery and the Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL

The majority of patients with advanced breast cancer develop osteolytic metastases in the skeleton, which lead to such complications as pain, fractures, hypercalcemia and a general decrease in the quality of life. Current therapies for bone metastases are not curative in nature. Thus, new treatments are needed for osteolytic bone metastasis of breast cancer. Conditionally replicating adenoviruses (CRADs) are a new class of anti-cancer agents that offer the potential ability to infect and lyse all the cells of a tumor. In clinical trials, replicating adenoviruses have exhibited safety but not the desired level of efficacy, demonstrating a need for improvement. One approach to enhance the efficacy of a CRAD is to arm it with a therapeutic transgene. Osteoprotegerin (OPG), the recently described inhibitor of osteoclastic bone resorption, represents a promising candidate with which to arm a replicating adenovirus designed to treat osteolytic bone metastasis. We hypothesize that a replicating adenovirus armed with a gene for OPG will be able to inhibit breast cancer bone metastasis and reduce the tumor burden in the bone through two actions: direct lysis of the tumor cells by replication of the virus and inhibition of bone resorption by the production of OPG.

To explore this hypothesis, a two-component model system was employed in these proof-of-concept studies. Coinfection of cells with both wild-type adenovirus and a replication-defective E1-deleted adenoviral vector expressing OPG allows replication of the vector via transcomplementation of E1 proteins from the wild-type virus. Therefore, we constructed a replication-defective adenoviral vector expressing OPG fused to the Fc portion of human IgG, to prolong its half-life. It was first necessary to demonstrate that the expression of OPG does not inhibit the replication of the virus or reduce its oncolytic potency. To this end, MDA-MB-231 breast cancer cells were coinfectd with both Ad-OPG-Fc and the replication-competent wild-type Ad5, Ad300wt, to allow replication. Assays for viral DNA replication as well as both qualitative and quantitative assays of cell viability showed that the expression of OPG-Fc neither inhibited viral DNA replication nor reduced the oncolytic ability of the replicating adenovirus. Having shown the potential utility of an OPG-Fc expressing adenovirus *in vitro*, we are currently preparing *in vivo* studies using a murine model of osteolytic bone metastasis.

Keywords: Adenovirus; Cancer Gene Therapy;

Saturday, June 5, 2004 4:00 PM

Poster Session III: Targeted Cancer Therapies III (4:00 PM-7:00 PM)

Close Window